Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Taipei City Hospital
Modality
UNKNOWN
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06244550CT.gov Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Liver Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ganwei (this asset) | Taipei City Hospital | N/A | D · 30 |
| Pioglitazone | Yonsei University | P4 | BBB |
| Metformin | Taipei City Hospital | P4 | BBB |
| Empagliflozin | Military University Hospital, Prague | P4 | BB |
| 10-(1-methylpiperidin-4-ylidene)-5,10-dihydro-4H-benzo[5,6]cyclohepta[1,2-b]thiophen-4-one | Tanta University | P4 | BB |
| Glibenclamide | Takeda | P4 | BB |
| Hep-V Vax | University of Oxford | P4 | BB |
| Alpha Tocopherol | Tanta University | P4 | BB |
| Shen Pu Yang Gan Wan | Taipei Medical University WanFang Hospital | P4 | BB |
+42 more in the Liver Disorder cohort
Other indications for Ganwei
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | N/A | D · 30 |
| Fibrotic Liver Disease | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ganwei in Liver Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ganwei-liver-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →